Table 5 shows pre- and post-resection UCP2 and 4-HNE immunoscores stratified by potential clinical, surgical, and pathological risk factors for PHLF (age > 60 years, steatosis/fibrosis, cholangiocarcinoma, neoadjuvant chemotherapy, the Pringle maneuver, intraoperative transfusion, and extent of resection). The gene discussed is UCP2; the disease is steatosis.